Morningside Venture Invests Series A Round In US Gene Therapy Company

Apic Bio, Inc., an American gene therapy company for treatment of rare genetic diseases, has raised US$40 million, led by Chinese early-stage venture capital Morningside Venture Investments, according to a January 7 announcement. The round also saw participation from new investor, the ALS Investment Fund, and existing investors, such as The Alpha-1 Project (TAP) and […]

Morningside Venture Invests Series A Round In US Gene Therapy Company appeared first on China Money Network.

Read the original article: China Money Network